MedTrace Logo

Administration of Chlorpromazine as a Treatment for COVID-19

NCT04354805 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2020-07-08

No results posted yet for this study

Summary

In this study, defined cases of COVID-19 confirmed with PCR, with a mild, moderate or severe pneumonia will be treated with chlorpromazine. The improvement in clinical \& laboratory manifestations will be evaluated in treated patient compared to control group.

Conditions

Interventions

DRUG

Chlorpromazine

(Oral dose of 50 mg/ day for 3 days then doubled to 100mg/day for further 11 days)

Sponsors & Collaborators

  • Noha Mahmoud Nasreldin Hassan

    collaborator UNKNOWN

  • Cairo University

    lead OTHER

Principal Investigators

  • Ahmed Rezk · Cairo University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-01
Primary Completion
2020-10-31
Completion
2020-11-30
FDA Drug
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04354805 on ClinicalTrials.gov